Search results
Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
Reuters via Yahoo News· 2 months agoThe treatment, tested in patients with advanced hepatocellular carcinoma (HCC), met the main goal of...
Is Exelixis' (EXEL) Growth Story Likely to Continue?
Zacks via Yahoo Finance· 2 years agoExelixis EXEL, an oncology-focused company, maintains momentum on the back of the solid performance of its lead drug Cabometyx amid stiff competition...
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Benzinga via Yahoo Finance· 2 years agoHC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ:...
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In...
Benzinga via Yahoo Finance· 2 years agoBeiGene Limited (NASDAQ: BGNE) shared updates from its solid tumor development program for...
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
Zacks via Yahoo Finance· 2 months agoBristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell...
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced detailed results from the ongoing phase III study, COSMIC-313. The...
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced that it entered into an exclusive license agreement with Ryvu...
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
Zacks via Yahoo Finance· 1 year agoExelixis EXEL announced preliminary financial results for the fourth quarter and full year 2022 and...
Signs and Symptoms That Thyroid Cancer Is Metastasizing
Verywell Health via Yahoo News· 3 months agoMedically reviewed by Kelly Wood, MD Thyroid cancer can become metastatic when cancer cells...
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
Zacks via Yahoo Finance· 2 years agoExelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with...